A prospective cohort to assess patient's tolerability for endoscopic therapy of Barrett's esphagus
Recruiting
- Conditions
- Barrett's Esophagus, Barrett's neoplasia, endoscopic treatment, endoscopic ablation, RFA, cryoablation, endoscopic resection, EMR, ESD
- Registration Number
- NL-OMON26070
- Lead Sponsor
- Sint Antonius Hospital, University Medical Center Utrecht, Academic Medical Center Amsterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
All patients (all age, both sexes) undergoing endoscopic therapy for Barrett's esophagus, that consent to complete a 14-days digital diary post-procedure
Exclusion Criteria
No access to e-mail
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative pain through 14 days, defined as the area under the curve for a pain versus time (14 days) plot
- Secondary Outcome Measures
Name Time Method Cumulative dysphagia, cumulative use of analgesics, peak pain score, duration of pain
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are associated with post-procedural pain after RFA or cryoablation in Barrett's esophagus patients?
How does cryoablation compare to RFA in terms of pain management and patient tolerability for Barrett's neoplasia?
What biomarkers in NL-OMON26070 predict patient response to endoscopic ablation for Barrett's esophagus subtypes?
What adverse events are reported with endoscopic resection (EMR/ESD) versus ablation in Barrett's patients?
Are there combination therapies with PPIs or NSAIDs that improve tolerability after endoscopic Barrett's treatment in NL-OMON26070?